What is Zacks Research’s Estimate for SRPT Q1 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for shares of Sarepta Therapeutics in a research note issued to investors on Monday, January 6th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $1.90 for the quarter, down from their prior estimate of $1.98. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.16 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.63 EPS, Q3 2025 earnings at $2.60 EPS, Q4 2025 earnings at $2.83 EPS, FY2025 earnings at $9.95 EPS, Q1 2026 earnings at $3.04 EPS, Q2 2026 earnings at $3.56 EPS, Q3 2026 earnings at $3.53 EPS, Q4 2026 earnings at $3.53 EPS and FY2026 earnings at $13.66 EPS.

Several other equities analysts have also commented on SRPT. UBS Group increased their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research report on Wednesday, November 27th. Royal Bank of Canada reissued an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Raymond James reissued an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $124.79 on Thursday. The firm has a market capitalization of $11.92 billion, a P/E ratio of 99.83 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a 50 day moving average price of $122.11 and a 200 day moving average price of $131.33. Sarepta Therapeutics has a 52 week low of $102.15 and a 52 week high of $173.25.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth approximately $4,771,000. Simplify Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after buying an additional 88,474 shares during the period. Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after buying an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC increased its stake in shares of Sarepta Therapeutics by 547.9% during the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after buying an additional 116,800 shares during the period. Finally, Larson Financial Group LLC increased its stake in Sarepta Therapeutics by 1,649.8% in the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after purchasing an additional 8,249 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.